Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb–IIIa: Is there a foetal risk?

Léticée, N.; Kaplan, C.; Lémery, D.

doi:10.1016/j.ejogrb.2005.02.011

Cited by 38 publications

(64 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, 49 patients were identified in case reports and were treated with rFVIIa for 36 bleeding episodes and 29 surgical procedures . Patients ranged in age from 1 to 60 years; 53% were female and 47% were male (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…In all, 40 case reports were identified that included 49 patients in whom rFVIIa was used as part of their treatment regimen; in six case reports, the same patient was treated for bleeding episodes and surgical procedures. Twenty‐four case reports described 29 patients treated for 36 bleeding episodes, and 22 case reports described 27 patients treated for 29 invasive, surgical or dental procedures.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature

et al. 2014

View full text Add to dashboard Cite

Glanzmann's thrombasthenia (GT) is a rare bleeding disorder characterized by a quantitative or qualitative defect of glycoprotein IIb/IIIa on the platelet membrane. Managing bleeding episodes is often difficult, and a variety of modalities have been used, including platelet transfusions, recombinant factor VIIa (rFVIIa), and other supportive care. The aim of this review was to present the clinical experience with rFVIIa bolus infusion (rFVIIa BI) for treatment of bleeding episodes and prevention of bleeding during surgical procedures in patients with GT. A literature search was performed to identify rFVIIa-treated patients with GT. Overall, one international survey, one open-label study, and 40 case reports identified 172 bleeding episodes treated with rFVIIa and 62 procedures covered with rFVIIa. In the international survey, rFVIIa BI was used for 96 bleeding episodes in 59 patients. Recombinant FVIIa was effective in 76 bleeding episodes (79%). Of 34 surgical procedures, 25 procedures received rFVIIa BI with 92% bleeding-prevention efficacy. The open-label study reported 28 patients with 28 rFVIIa BI-treated bleeds, and 26 (93%) bleeding episodes responded to rFVIIa. Published case reports revealed that 25 (69%) of 36 bleeds and 27 (96%) of 28 surgeries responded to rFVIIa BI treatment. Overall, 26 adverse events were reported in 19 patients, including five thromboembolic events in two patients where a possible relationship with rFVIIa could not be excluded. Two large studies and 40 case reports provide a literature base to support the efficacy and safety of rFVIIa BI in patients with GT.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Neonatal bleeding complications were reported in 10.0% (8/80; maternal diagnosis being GT n = 42, BSS n = 29, PT‐VWD n = 5, TxA2 n = 3 and P2Y12 n = 1) of deliveries with data on neonatal outcome. These included one foetal death due to severe third trimester gastrointestinal bleeding (maternal BSS), one in utero foetal death due to intracranial haemorrhage (maternal GT), one neonatal death six hours after delivery due to antepartum intracranial haemorrhage (maternal BSS), one neonatal death 48 hours after delivery due to haemolytic disease of the newborn (maternal GT), one neonate suffering from bruising after vaginal delivery (maternal GT) and three neonates that developed petechiae and ecchymoses shortly after caesarean sections (maternal BSS in all three cases) . In 6/8 deliveries with neonatal bleeding complications, the presence of alloantibodies was investigated, and in all six, either antiplatelet or anti‐HLA antibodies were present.…”

Section: Resultsmentioning

confidence: 99%

Menstrual and obstetrical bleeding in women with inherited platelet receptor defects—A systematic review

et al. 2020

View full text Add to dashboard Cite

Introduction Women with inherited platelet receptor defects (IPRD) may have an increased risk of heavy menstrual bleeding (HMB) and postpartum haemorrhage (PPH). Aim To present a systematic overview of the literature on the prevalence and management of menstrual and obstetrical bleeding in women with IPRD. Methods Electronic databases were searched for original patient data on the prevalence and management of HMB and PPH in women with known IPRD or who were being investigated for IPRD. Results Sixty‐nine papers (61 case reports/series and 8 cohort studies) were included. Overall, studies were rated as ‘poor quality’. The included cohort studies reported HMB in 25% (13/52) of women with Bernard‐Soulier syndrome and in 22.1% (34/154) of women with Glanzmann thrombasthenia. In total, 164 deliveries in women with IPRD were described. Excessive bleeding occurred in 16.9% (11/65) of deliveries described in the largest cohort. PPH occurred in 63.2% (55/87) of deliveries described in case reports/series. PPH occurred in 73.7% (14/19) of deliveries that were not covered by prophylaxis compared with 54.2% (32/59) of deliveries that were (OR = 2.36, 95% CI 0.75‐7.40). Neonatal bleeding complications were reported in 10.0% (8/80) of deliveries. In all (6/6) deliveries with neonatal bleeding complications wherein the presence of alloantibodies was investigated, either antiplatelet or anti‐HLA antibodies were detected. Discussion/Conclusion Menstrual and particularly obstetrical bleeding problems frequently occur in women with IPRD, based on small case reports and series of poor quality. International collaboration, preferably on prospective studies, is needed to improve clinical management of women‐specific bleeding in IPRD.

show abstract

“…It had been suggested that fertility may be impaired in GT due to repeated ovarian hemorrhage . Letecie et al reported a case of in‐utero death at 31 weeks of gestation due to ICH in the fetus of an immunized GT mother. Siddiq et al performed a systemic review of the literature for pregnancy outcomes in patients with GT and found 40 pregnancies in 35 women that resulted in 38 live births.…”

Section: Discussionmentioning

confidence: 99%

From thrombasthenia to next generation thrombocytopenia: Neonatal alloimmune thrombocytopenia induced by maternal Glanzmann thrombasthenia

Barg

Hauschner

Luboshitz

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb–IIIa: Is there a foetal risk?

Cited by 38 publications

References 14 publications

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature

Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature

Menstrual and obstetrical bleeding in women with inherited platelet receptor defects—A systematic review

From thrombasthenia to next generation thrombocytopenia: Neonatal alloimmune thrombocytopenia induced by maternal Glanzmann thrombasthenia

Contact Info

Product

Resources

About